As organotypic cultures with elements of organ architecture and functionality continue to advance, we find the relevance of in vitro work being boosted, a trend driven by the increasing availability of high-quality human cells through stem cell technologies. At CAAT, we’ve been at the forefront of these developments and are continuously promoting their progression.

In our continuous engagement with diverse stakeholders, we’ve identified a pivotal need: to augment our cutting-edge technical innovations with stringent quality assurance measures. This understanding has steered our ongoing initiatives, including Good Cell Culture Practice (GCCP), the standardization of in vitro reporting, and the formulation of in vitro risk-of-bias assessments.

Building on this foundation, we’re excited to launch the P4M—Public Private Partnership for Performance Standards for Microphysiological Systems. This initiative, which is coordinated by Lena Smirnova, PHD, aims to foster a discussion about performance standards for microphysiological systems (MPS).

As a new initiative, we invite all stakeholders to join us in a dialogue about performance standards for MPS. We aim to address questions including:

• What constitutes an MPS in cell culture?
• How can we define a ‘good’ MPS in terms of fit-for-purpose, reproducibility, relevance, and validity?
• What is the required level of documentation and reporting for an MPS?
• How can a lab demonstrate proficiency in testing with an MPS?
• What quality assurance and management measures need to be implemented?

We extend our invitation to potential partners across academia, regulatory agencies, industry, NGOs, and other sectors to join us in this endeavor.

Reach out to us at caat@jhu.edu and be part of this exciting venture that is set to redefine the future of in vitro work.